127 related articles for article (PubMed ID: 22608105)
1. Costs and clinical outcomes associated with use of ranolazine for treatment of angina.
Phelps CE; Buysman EK; Gomez Rey G
Clin Ther; 2012 Jun; 34(6):1395-1407.e4. PubMed ID: 22608105
[TBL] [Abstract][Full Text] [Related]
2. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris.
Ling H; Packard KA; Burns TL; Hilleman DE
Am J Cardiovasc Drugs; 2013 Dec; 13(6):407-12. PubMed ID: 23873327
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with ranolazine in a veteran population with chronic stable angina.
Reeder DN; Gillette MA; Franck AJ; Frohnapple DJ
Ann Pharmacother; 2012 Jan; 46(1):42-50. PubMed ID: 22215689
[TBL] [Abstract][Full Text] [Related]
4. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris.
Kohn CG; Parker MW; Limone BL; Coleman CI
Am J Cardiol; 2014 Apr; 113(8):1306-11. PubMed ID: 24560062
[TBL] [Abstract][Full Text] [Related]
6. Ranolazine (Ranexa) for chronic stable angina.
Ndegwa S
Issues Emerg Health Technol; 2007 Jun; (99):1-6. PubMed ID: 17595750
[TBL] [Abstract][Full Text] [Related]
7. Ranolazine: new drug. Stable angina: not worth the risk.
Prescrire Int; 2009 Aug; 18(102):148-7. PubMed ID: 19743543
[TBL] [Abstract][Full Text] [Related]
8. Ranolazine for the management of coronary artery disease.
Cheng JW
Clin Ther; 2006 Dec; 28(12):1996-2007. PubMed ID: 17296457
[TBL] [Abstract][Full Text] [Related]
9. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Stone PH; Gratsiansky NA; Blokhin A; Huang IZ; Meng L;
J Am Coll Cardiol; 2006 Aug; 48(3):566-75. PubMed ID: 16875985
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
Koren MJ; Crager MR; Sweeney M
J Am Coll Cardiol; 2007 Mar; 49(10):1027-34. PubMed ID: 17349881
[TBL] [Abstract][Full Text] [Related]
11. Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial.
Arnold SV; Morrow DA; Lei Y; Cohen DJ; Mahoney EM; Braunwald E; Chan PS
Circ Cardiovasc Qual Outcomes; 2009 Jul; 2(4):344-53. PubMed ID: 20031860
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions.
Page RL; Ghushchyan V; Read RA; Hartsfield CL; Koch BR; Nair KV
Am J Cardiol; 2015 Nov; 116(9):1321-8. PubMed ID: 26358510
[TBL] [Abstract][Full Text] [Related]
13. Medical therapy versus myocardial revascularization in chronic coronary syndrome and stable angina.
Deedwania PC; Carbajal EV
Am J Med; 2011 Aug; 124(8):681-8. PubMed ID: 21787900
[TBL] [Abstract][Full Text] [Related]
14. Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial.
Weisz G; Farzaneh-Far R; Ben-Yehuda O; Debruyne B; Montalescot G; Lerman A; Mahmud E; Alexander KP; Ohman EM; White HD; Olmsted A; Walker GA; Stone GW
Am Heart J; 2013 Dec; 166(6):953-959.e3. PubMed ID: 24268208
[TBL] [Abstract][Full Text] [Related]
15. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
Melloni C; Newby LK
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
[TBL] [Abstract][Full Text] [Related]
16. Ranolazine: a new option in the management of chronic stable angina.
Dobesh PP; Trujillo TC
Pharmacotherapy; 2007 Dec; 27(12):1659-76. PubMed ID: 18041887
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.
Rousseau MF; Pouleur H; Cocco G; Wolff AA
Am J Cardiol; 2005 Feb; 95(3):311-6. PubMed ID: 15670536
[TBL] [Abstract][Full Text] [Related]
18. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.
Thadani U
Expert Opin Pharmacother; 2012 Dec; 13(17):2555-63. PubMed ID: 23121448
[TBL] [Abstract][Full Text] [Related]
19. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
Chaitman BR; Skettino SL; Parker JO; Hanley P; Meluzin J; Kuch J; Pepine CJ; Wang W; Nelson JJ; Hebert DA; Wolff AA;
J Am Coll Cardiol; 2004 Apr; 43(8):1375-82. PubMed ID: 15093870
[TBL] [Abstract][Full Text] [Related]
20. Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial.
Sendón JL; Lee S; Cheng ML; Ben-Yehuda O;
Eur J Prev Cardiol; 2012 Oct; 19(5):952-9. PubMed ID: 22689417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
